Product Overview
Dragon Pharma PT-141 arrives as a single 10 mg vial of lyophilised bremelanotide, a melanocortin receptor agonist that works inside the central nervous system. The molecule has nothing in common with the vascular route taken by Viagra DP 50mg or Cialis 20mg. Those medicines relax smooth muscle in the pelvic arteries; bremelanotide acts on the signalling that drives desire and arousal. Anyone shopping for a quicker vascular answer is looking at the wrong compound.
Chemically the peptide is the active metabolite of Melanotan II with the terminal amide group missing, which explains why the two molecules share the pigmentation side of their profile and why the melanocortin family is usually discussed as one group. Binding is strongest at the MC4 receptor. The readout in the reference work is subjective arousal rather than blood flow, and the compound does not touch the androgen receptor, does not build muscle and is not a hormone replacement.
Only one bremelanotide product carries a registered label, and it is not this vial. The approved injection is licensed for low libido in premenopausal women and given at 1.75 mg subcutaneously on demand, not on a daily schedule. The Dragon Pharma vial is a research-grade powder without a label of its own, so that approved number is orientation and nothing more. Where low libido comes from low testosterone instead, the answer sits on the androgen side of the problem, with HCG 5000 iu or the smaller HCG 2500 iu pack as the relevant material rather than a melanocortin peptide.
Dosage Protocol
No source consulted for this card publishes a dosing schedule for a research vial of bremelanotide, and the table says where the data is missing rather than inventing a titration curve. The registered product is listed separately as a medical reference point.
| Beginner | No confirmed figures for a research vial; the registered product is used on demand rather than as a course |
| Intermediate | No confirmed figures for a research vial; 1.75 mg subcutaneously is the approved prescription dose and not a powder schedule |
| Advanced | No confirmed escalation; increasing the amount is not described in the sources as producing a stronger response |
| Female | 1.75 mg subcutaneously, the approved on-demand dose for premenopausal hypoactive sexual desire disorder - a reference from the registered product |
| Administration | Subcutaneous injection, described in the material as abdomen or thigh; the effect develops within one to two hours; a second injection inside the same day is not described in the sources and repeated use is linked to pigmentation |
The arithmetic for the vial: adding 2 ml of bacteriostatic water to 10 mg of powder gives 5 mg per ml, which places the 1.75 mg reference at 0.35 ml, the 35 unit mark on a U-100 barrel. That is a concentration calculation, not a recommendation, and it borrows a number that belongs to a different product.
Positioning and Combinations
No published work combines this molecule with other compounds, so the cards below show where it sits next to other Dragon Pharma products instead of offering a stack to copy. Each tile opens the product page.
What to Expect
- Onset and duration. The effect develops within one to two hours of a subcutaneous injection and holds for a few hours, which fits an elimination half-life near 2.7 hours, with sources spreading it from 1.9 to 4.0 hours.
- Nausea is the headline effect. Roughly 40 percent against 8 percent on placebo in the trial data; it is usually short-lived and mild to moderate.
- Flushing, headache, injection site reactions. Frequent in the reported profile and normally transient.
- Skin darkening. Described with more frequent use, so the tolerance picture changes when the material is used often.
- Blood pressure. Changes are recorded in the labelling warnings of the registered form; the material is not intended for anyone with uncontrolled hypertension.
- What it does not do. There is no anabolic, androgenic or fat-loss activity to expect from a melanocortin peptide.
- Limit of the data. The vial has no approved dose, and a low libido driven by low testosterone belongs to a different conversation entirely.
Side Effects and Management
The profile is dominated by short autonomic effects rather than by organ toxicity, and frequency rises with the amount used.
Reconstitution, Storage and Follow-Up
The axis question is simple with this molecule: gonadal function is untouched, so no SERM step belongs here and there is nothing to restart. What does need a plan is the vial itself and the way tolerance is tracked.
